Longterm beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever
K Laskari, P Boura, GN Dalekos, A Garyfallos… - The Journal of …, 2017 - jrheum.org
Objective. To assess the efficacy and safety of the interleukin-1β (IL-1β) inhibitor
canakinumab in all adolescent and adult patients with familial Mediterranean fever (FMF) …
canakinumab in all adolescent and adult patients with familial Mediterranean fever (FMF) …
Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature …
S Eren Akarcan, S Dogantan, N Edeer Karaca… - Rheumatology …, 2020 - Springer
Familial Mediterranean fever (FMF) is the most common monogenic auto-inflammatory
disease characterized by recurrent attacks of fever and serositis. Although colchicine is the …
disease characterized by recurrent attacks of fever and serositis. Although colchicine is the …
Effectiveness of canakinumab in colchicine-and anakinra-resistant or-intolerant adult familial Mediterranean fever patients: a single-center real-life study
H Babaoglu, O Varan, H Kucuk, N Atas… - JCR: Journal of …, 2020 - journals.lww.com
Objective We aimed to present our single-center real-life experience of canakinumab use in
adult patients with familial Mediterranean fever (FMF). Methods Data were derived from the …
adult patients with familial Mediterranean fever (FMF). Methods Data were derived from the …
[HTML][HTML] Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
Objective Familial Mediterranean fever (FMF) is the most common inherited monogenic
autoinflammatory disease worldwide. It is caused by loss-of-function mutations in the MEFV …
autoinflammatory disease worldwide. It is caused by loss-of-function mutations in the MEFV …
Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment
As an autosomal recessive autoinflammatory disease, treatment of Familial Mediterranean
fever (FMF) has still gaps. Clinical studies are proving the safety and efficacy of colchicine in …
fever (FMF) has still gaps. Clinical studies are proving the safety and efficacy of colchicine in …
Canakinumab in children with familial Mediterranean fever: a single-center, retrospective analysis
RM Kisla Ekinci, S Balci, D Dogruel, DU Altintas… - Pediatric Drugs, 2019 - Springer
Abstract Introduction Familial Mediterranean fever (FMF) is an autoinflammatory disease
characterized by interleukin (IL)-1 overproduction. Colchicine is the mainstay drug in the …
characterized by interleukin (IL)-1 overproduction. Colchicine is the mainstay drug in the …
[HTML][HTML] IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
BM Köhler, HM Lorenz, N Blank - European journal of …, 2018 - ncbi.nlm.nih.gov
Objective Approximately 10%–20% of patients with familial Mediterranean fever (FMF) show
an inadequate response to colchicine. In our cohort study, patients with FMF with or without …
an inadequate response to colchicine. In our cohort study, patients with FMF with or without …
The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever: a systematic review of the literature
M Kacar, S Savic, JCH van der Hilst - Journal of inflammation …, 2020 - Taylor & Francis
Abstract Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory
disorder. In most patients, treatment with colchicine can prevent attacks of fever and …
disorder. In most patients, treatment with colchicine can prevent attacks of fever and …
[HTML][HTML] Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
A Şahin, ME Derin, F Albayrak, B Karakaş… - Advances in …, 2020 - SciELO Brasil
İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease
characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) …
characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) …
Canakinumab investigated for treating familial Mediterranean fever
R Haviv, PJ Hashkes - Expert opinion on biological therapy, 2016 - Taylor & Francis
ABSTRACT Introduction: Familial Mediterranean fever (FMF) is the most common hereditary
autoinflammatory syndrome. The treatment of choice is colchicine. However,~ 40% of …
autoinflammatory syndrome. The treatment of choice is colchicine. However,~ 40% of …